Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | SCN1A | P35498 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.32 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13547345 | 1.00 | MEN1 (0.32) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL22142244 | 1.00 | MEN1 (0.32) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL22433108 | 0.95 | SMN1; SMN2 (0.35) | LMNACXCR4SMN1; SMN2ALDH1A1EPHX1 | |
| SCHEMBL13547239 | 0.93 | ALDH1A1 (0.36) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL104705 | 0.89 | LMNA (0.37) | MEN1LMNACYP2D6HRH1SCN1A | |
| Hydrochloric Acid SCHEMBL2253109 | 0.87 | MEN1 (0.35) | MEN1LMNACYP2D6HRH1SCN1A | |
| SCHEMBL23260533 | 0.81 | SSTR4 (0.35) | EPHX1 | |
| SCHEMBL27250923 | 0.81 | — | — | |
| SCHEMBL1104704 | 0.80 | SLC6A1 (0.37) | LMNACYP2D6KMT2ASMN1; SMN2 | |
| SCHEMBL14093032 | 0.80 | SLC6A1 (0.37) | LMNACYP2D6KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | ASIA VISION LIMITED (CN) | 2024-07-18 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | THE UNIVERSITY OF THE WEST INDIES (TT) | 2023-11-30 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | INFLAZOME LTD (IE) | 2023-02-02 | — | — | US | disclosed |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | BEETLEJUICE SA LLC, AS PURCHASER AGENT | 2022-03-10 | — | — | US | disclosed |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | CELGENE CORPORATION (US) | 2021-11-09 | — | — | US | disclosed |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-07-20 | — | — | US | disclosed |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2010-09-16 | — | — | US | disclosed |
| US-7737137-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2010-06-15 | — | — | US | disclosed |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | ABBOTT LABORATORIES (US) | 2008-12-18 | — | — | US | disclosed |
| WO-2008140792-A1 | DERIVATIVES OF FLUORENE, ANTHRACENE, XANTHENE, DIBENZOSUBERONE AND ACRIDINE AND USES THEREOF | AVALON PHARMACEUTICALS (US) | 2008-11-20 | — | — | WO | disclosed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435833-B2 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES (US) | 2008-10-14 | — | — | US | disclosed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | ABBOTT LABORATORIES (US) | 2008-03-27 | — | — | US | disclosed |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076819-A1 | INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME | HSD11B1, HSD11B2, HSD17B1 | MEN1 1773/4885LMNA 3653/4885CYP2D6 182/4885 |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | MEN1 1294/4885LMNA 3799/4885CYP2D6 1275/4885 |
| US-20230382926-A1 | COMPOUNDS AND USES THEREOF | CFTR, CCL11, CEL | MEN1 348/4885LMNA 3672/4885CYP2D6 602/4885 |
| US-20100267738-A1 | NOVEL AMIDE AND AMIDINE DERIVATIVES AND USES THEREOF | HSD11B2, HSD11B1, HSD17B2 | MEN1 1978/4885LMNA 3575/4885CYP2D6 1094/4885 |
| US-20240239792-A1 | MODULATORS OF BCL-2 OR BCL-2/BCL-XL AND USES THEREOF | BCL2, BCL2L2, BCL2L1 | MEN1 4422/4885LMNA 1883/4885CYP2D6 4042/4885 |
| US-12036209-B2 | Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MEN1 2168/4885LMNA 2696/4885CYP2D6 4827/4885 |
| US-11065231-B2 | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides | IRAK1, IRAK4, IRAK2 | MEN1 2454/4885LMNA 2783/4885CYP2D6 4812/4885 |
| US-20080312214-A1 | Inhibitors of the 11-Beta-Hydroxysteroid Dehydrogenase Type 1 Enzyme | HSD11B1, HSD17B1, HSD11B2 | MEN1 1267/4885LMNA 2073/4885CYP2D6 714/4885 |
| US-20230017597-A1 | 8-SUBSTITUTED STYRYL XANTHINE DERIVATIVES AND USES THEREOF | ADORA2A, ADORA3, ADORA2B | MEN1 4757/4885LMNA 2973/4885CYP2D6 1125/4885 |
| US-20080045497-A1 | SUBSTITUTED ANILINE DERIVATIVES | DPM1, ERG28, IL4I1 | MEN1 552/4885LMNA 4262/4885CYP2D6 322/4885 |
| US-11168093-B2 | Thienopyridine inhibitors of RIPK2 | RIPK2, RIPK1, RIPK4 | MEN1 3296/4885LMNA 3725/4885CYP2D6 2953/4885 |
| US-20230037255-A1 | NOVEL SULFONAMIDE CARBOXAMIDE COMPOUNDS | NLRP3, NOD1, NLRP1 | MEN1 4122/4885LMNA 1266/4885CYP2D6 602/4885 |
| US-20220072006-A1 | PRO-DRUGS OF RILUZOLE AND THEIR METHOD OF USE FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS | CYP1A2, CYP3A5, UGT1A1 | MEN1 4790/4885LMNA 202/4885CYP2D6 4/4885 |
| US-20100233123-A1 | PHOSPHOTHIOPHENE AND PHOSPHOTHIAZOLE HCV POLYMERASE INHIBITORS | PPP3CB, POLR2E, PSAT1 | MEN1 4874/4885LMNA 4332/4885CYP2D6 588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.